Chemotherapeutic Regimens and Chemotherapy-Free Intervals Influence the Survival of Patients with Recurrent Advanced Epithelial Ovarian Carcinoma: A Retrospective Population-Based Study
Abstract
:1. Introduction
2. Patients and Methods
2.1. Study Design
2.2. Study Population
2.3. Second-Line Salvage Chemotherapy
2.4. Statistical Analyses
3. Results
3.1. Patient Characteristics
3.2. Patients Treated with Platinum Combined with Paclitaxel Had the Best Five-Year OS
3.3. TFIp Impacted Five-Year OS in Patients with PS Recurrent Advanced EOC
3.4. Patients with TFIp > 12 Months Had Better Five-Year OS Than Those with TFIp of 6–12 Months
4. Discussion
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Webb, P.M.; Jordan, S.J. Epidemiology of epithelial ovarian cancer. Best Pr. Res. Clin. Obstet. Gynaecol. 2017, 41, 3–14. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Observatory TGC. Ovarian Cancer Fact Sheet. 2018. Available online: https://gco.iarc.fr/today/data/factsheets/cancers/25-Ovary-fact-sheet.pdf (accessed on 1 September 2019).
- Cancer Registry, T. Cancer Registry Annual Report 2016, Taiwan. Available online: https://www.hpa.gov.tw/Pages/ashx/File.ashx?FilePath=~/File/Attach/10227/File_11644.pdf (accessed on 1 September 2019).
- Health Promotion Administration. Executive Yuan, Taiwan, Cancer Registry Report 2015; Health Promotion Administration: Taipei City, Taiwan, 2015. [Google Scholar]
- Chiang, Y.-C.; Chen, C.-A.; Chiang, C.-J.; Hsu, T.-H.; Lin, M.-C.; You, S.-L.; Cheng, W.-F.; Lai, M.-S. Trends in incidence and survival outcome of epithelial ovarian cancer: 30-year national population-based registry in Taiwan. J. Gynecol. Oncol. 2013, 24, 342–351. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Foley, O.W.; Rauh-Hain, J.A.; Del Carmen, M.G. Recurrent epithelial ovarian cancer: An update on treatment. Oncology 2013, 27, 288–294. [Google Scholar] [PubMed]
- Wilson, M.K.; Pujade-Lauraine, E.; Aoki, D.; Mirza, M.R.; Lorusso, D.; Oza, A.M.; du Bois, A.; Vergote, I.; Reuss, A.; Bacon, M.; et al. Fifth Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup: Recurrent disease. Ann. Oncol. 2017, 28, 727–732. [Google Scholar] [CrossRef] [PubMed]
- Pignata, S.; Lorusso, D.; Joly, F.; Gallo, C.; Colombo, N.; Sessa, C.; Bamias, A.; Salutari, V.; Selle, F.; Frezzini, S.; et al. Carboplatin-based doublet plus bevacizumab beyond progression versus carboplatin-based doublet alone in patients with platinum-sensitive ovarian cancer: A randomised, phase 3 trial. Lancet Oncol. 2021, 22, 267–276. [Google Scholar] [CrossRef]
- Pfisterer, J.; Shannon, C.M.; Baumann, K.; Rau, J.; Harter, P.; Joly, F.; Sehouli, J.; Canzler, U.; Schmalfeldt, B.; Dean, A.P.; et al. Bevacizumab and platinum-based combinations for recurrent ovarian cancer: A randomised, open-label, phase 3 trial. Lancet Oncol. 2020, 21, 699–709. [Google Scholar] [CrossRef]
- Madariaga, A.; Bowering, V.; Ahrari, S.; Oza, A.M.; Lheureux, S. Manage wisely: Poly (ADP-ribose) polymerase inhibitor (PARPi) treatment and adverse events. Int. J. Gynecol. Cancer 2020, 30, 903–915. [Google Scholar] [CrossRef] [Green Version]
- Luvero, D.; Milani, A.; Ledermann, J.A. Treatment options in recurrent ovarian cancer: Latest evidence and clinical potential. Ther. Adv. Med Oncol. 2014, 6, 229–239. [Google Scholar] [CrossRef] [Green Version]
- Network, N.C.C. Ovarian Cancer Including Fallopian Tube Cancer and Primary Peritoneal Cancer, Clinical Practice Guidelines in Oncology. J. Natl. Compr. Canc. Netw. 2021, 19, 191–226. [Google Scholar]
- Tomao, F.; D’Incalci, M.; Biagioli, E.; Peccatori, F.A.; Colombo, N. Restoring platinum sensitivity in recurrent ovarian cancer by extending the platinum-free interval: Myth or reality? Cancer 2017, 123, 3450–3459. [Google Scholar] [CrossRef] [Green Version]
- Colombo, N. Optimising the treatment of the partially platinum-sensitive relapsed ovarian cancer patient. Eur. J. Cancer Suppl. 2014, 12, 7–12. [Google Scholar] [CrossRef] [Green Version]
- Hsiao, S.-M.; Chen, C.-A.; Lin, H.-H.; Hsieh, C.-Y.; Wei, L.-H. Phase II trial of carboplatin and distearoylphosphatidylcholine pegylated liposomal doxorubicin (Lipo-Dox®) in recurrent platinum-sensitive ovarian cancer following front-line therapy with paclitaxel and platinum. Gynecol. Oncol. 2009, 112, 35–39. [Google Scholar] [CrossRef] [PubMed]
- Loizzi, V.; Chan, J.K.; Osann, K.; Cappuccini, F.; DiSaia, P.J.; Berman, M.L. Survival outcomes in patients with recurrent ovarian cancer who were treated with chemoresistance assay-guided chemotherapy. Am. J. Obstet. Gynecol. 2003, 189, 1301–1307. [Google Scholar] [CrossRef]
- Pujade-Lauraine, E.; Wagner, U.; Aavall-Lundqvist, E.; Gebski, V.; Heywood, M.; Vasey, P.A.; Volgger, B.; Vergote, I.; Pignata, S.; Ferrero, A.; et al. Pegylated Liposomal Doxorubicin and Carboplatin Compared With Paclitaxel and Carboplatin for Patients With Platinum-Sensitive Ovarian Cancer in Late Relapse. J. Clin. Oncol. 2010, 28, 3323–3329. [Google Scholar] [CrossRef] [PubMed]
- Raja, F.A.; Counsell, N.; Colombo, N.; Pfisterer, J.; Du Bois, A.; Parmar, M.K.; Vergote, I.B.; Gonzalez-Martin, A.; Alberts, D.S.; Plante, M.; et al. Platinum versus platinum-combination chemotherapy in platinum-sensitive recurrent ovarian cancer: A meta-analysis using individual patient data. Ann. Oncol. 2013, 24, 3028–3034. [Google Scholar] [CrossRef] [PubMed]
- Huinink, W.T.B.; Gore, M.; Carmichael, J.; Gordon, A.; Malfetano, J.; Hudson, I.; Broom, C.; Scarabelli, C.; Davidson, N.; Spanczynski, M.; et al. Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. J. Clin. Oncol. 1997, 15, 2183–2193. [Google Scholar] [CrossRef] [PubMed]
- Wagner, U.; Marth, C.; Largillier, R.; Kaern, J.; Brown, C.J.; I Heywood, M.; Bonaventura, T.; Vergote, I.; Piccirillo, M.C.; Fossati, R.; et al. Final overall survival results of phase III GCIG CALYPSO trial of pegylated liposomal doxorubicin and carboplatin vs paclitaxel and carboplatin in platinum-sensitive ovarian cancer patients. Br. J. Cancer 2012, 107, 588–591. [Google Scholar] [CrossRef] [Green Version]
- ESMO Clinical Practice Guidelines: Gynaecological Cancers. Available online: https://www.esmo.org/guidelines/gynaecological-cancers (accessed on 17 June 2021).
- Lawrie, T.A.; Bryant, A.; Cameron, A.; Gray, E.; Morrison, J. Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer. Cochrane Database Syst. Rev. 2013, 7, CD006910. [Google Scholar] [CrossRef] [PubMed]
- Pignata, S.; C Cecere, S.; Du Bois, A.; Harter, P.; Heitz, F. Treatment of recurrent ovarian cancer. Ann. Oncol. 2017, 28 (Suppl 8), viii51–viii56. [Google Scholar] [CrossRef]
- Pignata, S.; Scambia, G.; Bologna, A.; Signoriello, S.; Vergote, I.B.; Wagner, U.; Lorusso, D.; Murgia, V.; Sorio, R.; Ferrandina, G.; et al. Randomized Controlled Trial Testing the Efficacy of Platinum-Free Interval Prolongation in Advanced Ovarian Cancer: The MITO-8, MaNGO, BGOG-Ov1, AGO-Ovar2.16, ENGOT-Ov1, GCIG Study. J. Clin. Oncol. 2017, 35, 3347–3353. [Google Scholar] [CrossRef]
- Rivankar, S. An overview of doxorubicin formulations in cancer therapy. J. Cancer Res. Ther. 2014, 10, 853–858. [Google Scholar] [CrossRef] [PubMed]
- Katsumata, N.; Yasuda, M.; Isonishi, S.; Takahashi, F.; Michimae, H.; Kimura, E.; Aoki, D.; Jobo, T.; Kodama, S.; Terauchi, F.; et al. Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): A randomised, controlled, open-label trial. Lancet Oncol. 2013, 14, 1020–1026. [Google Scholar] [CrossRef]
- Chan, J.K.; Brady, M.F.; Penson, R.T.; Huang, H.; Birrer, M.J.; Walker, J.L.; DiSilvestro, P.A.; Rubin, S.C.; Martin, L.P.; Davidson, S.A.; et al. Weekly vs. Every-3-Week Paclitaxel and Carboplatin for Ovarian Cancer. N. Engl. J. Med. 2016, 374, 738–748. [Google Scholar] [CrossRef] [Green Version]
- Kim, J.-W.; Mahner, S.; Wu, L.-Y.; Shoji, T.; Kim, B.-G.; Zhu, J.; Takano, T.; Park, S.-Y.; Kong, B.-H.; Wu, Q.; et al. Pazopanib Maintenance Therapy in East Asian Women With Advanced Epithelial Ovarian Cancer: Results From AGO-OVAR16 and an East Asian Study. Int. J. Gynecol. Cancer 2018, 28, 2–10. [Google Scholar] [CrossRef] [PubMed]
- Gladieff, L.; Ferrero, A.; De Rauglaudre, G.; Brown, C.; Vasey, P.; Reinthaller, A.; Pujade-Lauraine, E.; Reed, N.; Lorusso, D.; Siena, S.; et al. Carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in partially platinum-sensitive ovarian cancer patients: Results from a subset analysis of the CALYPSO phase III trial. Ann. Oncol. 2012, 23, 1185–1189. [Google Scholar] [CrossRef] [PubMed]
- Pignata, S.; Lorusso, D.; Joly, F.; Gallo, C.; Colombo, N.; Sessa, C.; Bamias, A.; Pisano, C.; Selle, F.; Zaccarelli, E.; et al. Chemotherapy plus or minus bevacizumab for platinum-sensitive ovarian cancer patients recurring after a bevacizumab containing first line treatment: The randomized phase 3 trial MITO16B-MaNGO OV2B-ENGOT OV17. J. Clin. Oncol. 2017, 36, 5506. [Google Scholar] [CrossRef]
- Lee, S.-P.; Hsu, H.-C.; Tai, Y.-J.; Chen, Y.-L.; Chiang, Y.-C.; Chen, C.-A.; Cheng, W.-F. Bevacizumab Dose Affects the Severity of Adverse Events in Gynecologic Malignancies. Front. Pharmacol. 2019, 10, 426. [Google Scholar] [CrossRef]
- Ruscito, I.; Bellati, F.; Ray-Coquard, I.; Mirza, M.R.; du Bois, A.; Gasparri, M.L.; Costanzi, F.; De Marco, M.P.; Nuti, M.; Caserta, D.; et al. Incorporating Parp-inhibitors in Primary and Recurrent Ovarian Cancer: A Meta-analysis of 12 phase II/III randomized controlled trials. Cancer Treat. Rev. 2020, 87, 102040. [Google Scholar] [CrossRef]
- Gyawali, B.; Iddawela, M. Bevacizumab in Advanced Cervical Cancer: Issues and Challenges for Low- and Middle-Income Countries. J. Glob. Oncol. 2017, 3, 93–97. [Google Scholar] [CrossRef]
- Monk, B.J.; Lammers, P.E.; Cartwright, T.; Jacobs, I. Barriers to the Access of Bevacizumab in Patients with Solid Tumors and the Potential Impact of Biosimilars: A Physician Survey. Pharmaceiticals 2017, 10, 19. [Google Scholar] [CrossRef] [Green Version]
- Rose, P.G.; Java, J.J.; Salani, R.; Geller, M.A.; Secord, A.A.; Tewari, K.S.; Bender, D.P.; Mutch, D.G.; Friedlander, M.L.; Van Le, L.; et al. Nomogram for Predicting Individual Survival After Recurrence of Advanced-Stage, High-Grade Ovarian Carcinoma. Obstet. Gynecol. 2019, 133, 245–254. [Google Scholar] [CrossRef] [PubMed]
- Aghajanian, C.; Blank, S.V.; Goff, B.A.; Judson, P.L.; Teneriello, M.G.; Husain, A.; Sovak, M.A.; Yi, J.; Nycum, L.R. OCEANS: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Chemotherapy With or Without Bevacizumab in Patients With Platinum-Sensitive Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer. J. Clin. Oncol. 2012, 30, 2039–2045. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Sehouli, J.; Chekerov, R.; Reinthaller, A.; Richter, R.; Gonzalez-Martin, A.; Harter, P.; Woopen, H.; Petru, E.; Hanker, L.C.; Keil, E.; et al. Topotecan plus carboplatin versus standard therapy with paclitaxel plus carboplatin (PC) or gemcitabine plus carboplatin (GC) or pegylated liposomal doxorubicin plus carboplatin (PLDC): A randomized phase III trial of the NOGGO-AGO-Study Group-AGO Austria and GEICO-ENGOT-GCIG intergroup study (HECTOR). Ann. Oncol. 2016, 27, 2236–2241. [Google Scholar] [CrossRef] [PubMed]
- Coleman, R.L.; Brady, M.F.; Herzog, T.J.; Sabbatini, P.; Armstrong, D.K.; Walker, J.L.; Kim, B.-G.; Fujiwara, K.; Tewari, K.S.; O’Malley, D.M.; et al. Bevacizumab and paclitaxel–carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): A multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2017, 18, 779–791. [Google Scholar] [CrossRef] [Green Version]
Characteristics | PT (N = 605) | PD (N = 204) | TOP (N = 109) | PLD (N = 120) | p | ||||
---|---|---|---|---|---|---|---|---|---|
N | % | N | % | N | % | N | % | % | |
Age | |||||||||
Mean (SD) | 53.64 (9.94) | 54.34 (10.68) | 54.70 (11.42) | 54.81 (10.81) | 0.53 | ||||
≤40 | 37 | 6.1 | 18 | 8.8 | 11 | 10.1 | 7 | 5.8 | 0.27 |
41–50 | 195 | 32.2 | 52 | 25.5 | 26 | 23.9 | 32 | 26.7 | |
51–60 | 220 | 36.4 | 77 | 37.8 | 36 | 33.0 | 43 | 35.8 | |
>60 | 153 | 25.3 | 57 | 27.9 | 36 | 33.0 | 38 | 31.7 | |
TFIp (months) | <0.001 | ||||||||
6–12 (N = 504) | 207 | 34.2 | 118 | 57.84 | 82 | 75.2 | 97 | 80.8 | |
>12 (N = 534) | 398 | 65.8 | 86 | 42.16 | 27 | 24.8 | 23 | 19.2 | |
Charlson Comorbidity Index | 0.52 | ||||||||
Score = 0 | 545 | 90.1 | 184 | 90.2 | 96 | 88.1 | 103 | 85.8 | |
Score ≥1 | 60 | 9.9 | 20 | 9.8 | 13 | 11.9 | 17 | 14.2 | |
Hospital Level | <0.001 | ||||||||
Public medical center | 220 | 36.4 | 128 | 62.8 | 38 | 34.9 | 46 | 38.3 | |
Public non-medical center | 11 | 1.8 | 1 | 0.5 | 0 | 0.0 | 2 | 1.7 | |
Private medical center | 256 | 42.3 | 60 | 29.4 | 36 | 33.0 | 53 | 44.2 | |
Private non-medical center | 118 | 19.5 | 15 | 7.3 | 35 | 32.1 | 19 | 15.8 |
N | Previous Lines of Therapy | TFIp | PFS | OS (p-Value) | HR HR, P | ||||
---|---|---|---|---|---|---|---|---|---|
CALYPSO | 1 | 2 | 6–12 | >12 | 0.82 (0.005) | 0.99 (0.94) | |||
PD | 466 | 87.6% | 12.4% | 35% | 65% | 11.3 | 30.7 | ||
PT | 507 | 82.6% | 17.3% | 36.1% | 63.9% | 9.4 | 33 | ||
HECTOR | n/a (0.414) | n/a (0.163) | |||||||
TP | 275 | 95.6% | 20% | 64% | 36% | 10 | 25 | ||
GC/PT/PD | 275 | 97.1% | 18.9% | 65.5% | 33.5% | 10 | 31 | ||
MITO-8 | 1.41 (0.025) | 1.38 (0.06) | |||||||
PC | 102 | 94.4% | 5.6% | 100% | 0 | 16.4 | 24.5 | ||
PLD | 97 | 93.5% | 6.5% | 100% | 0 | 12.8 | 21.8 | ||
OCEANS | 0.48 (<0.0001) | ||||||||
PGbev | 242 | 100% | 41.3% | 42.1% | 12.4 | n/a | |||
PG | 242 | 100% | 58.7% | 57.9% | 8.4 | n/a | |||
GOG213 | 6–12 | >12 | 0.628 (<0.001) | 0.829 (0.056) | |||||
PCbev | 337 | 100% | 27% | 73% | 13.8 | 42.2 | |||
PC | 337 | 100% | 25% | 75% | 10.4 | 37.3 | |||
AGO | 0.861 (0.012) | ||||||||
PDbev | 100% | 0 | 31% | 69% | 13.3 | n/a | |||
PGbev | 100% | 0 | 31% | 69% | 11.6 | n/a | |||
MITO16B | 0.51 (0.0001) | ||||||||
PCbev | 100% | 35% | 65% | 11.8 | n/a | ||||
PC | 100% | 36% | 64% | 8.8 | n/a | ||||
Huang et al. | 6–12 >12 | ||||||||
PT | 605 | 100% | 34.2% | 65.8% | n/a | 33.6 | 1.00 1.00 | ||
PD | 204 | 100% | 57.8% | 42.2% | n/a | 28.2 | 1.39 0.94 | ||
TOP | 109 | 100% | 75.2% | 24.8 | n/a | 21.8 | |||
PLD | 120 | 100% | 80.8% | 19.2% | n/a | 17.0 |
Regimens | 2-Year | 5-Year | ||||
---|---|---|---|---|---|---|
HR * | 95% CI | p | HR* | 95% CI | p | |
TFIp 6–12 months | ||||||
OS | ||||||
PT | 1.00 | (Reference) | 1.00 | (Reference) | ||
PD | 1.39 | 0.98–1.99 | 0.067 | 1.36 | 1.03–1.79 | 0.031 |
TOP | 1.71 | 1.19–2.45 | 0.0035 | 1.41 | 1.06–1.89 | 0.018 |
PLD | 2.30 | 1.66–3.19 | <0.0001 | 1.86 | 1.42–2.43 | <0.0001 |
TFIp > 12 months | ||||||
OS | ||||||
PT | 1.00 | (Reference) | 1.00 | (Reference) | ||
PD | 0.94 | 0.59–1.50 | 0.79 | 1.13 | 0.82–1.57 | 0.46 |
TOP | 1.64 | 0.85–3.18 | 0.014 | 1.36 | 0.80–2.28 | 0.25 |
PLD | 1.46 | 0.67–3.15 | 0.34 | 1.59 | 0.96–2.61 | 0.07 |
Regimens | Platinum (N = 809) | Non-Platinum (N = 229) | ||||
---|---|---|---|---|---|---|
HR * | 95% CI | p | HR* | 95% CI | p | |
Five-year OS | ||||||
TFIp 6–12 months | 1.00 | (Reference) | 1.00 | (Reference) | ||
TFIp > 12 months | 0.57 | 0.47–0.68 | <0.001 | 0.56 | 0.38–0.82 | 0.003 |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Huang, H.-Y.; Chiang, C.-J.; Chen, Y.-Y.; You, S.-L.; Hsu, H.-C.; Tang, C.-H.; Cheng, W.-F. Chemotherapeutic Regimens and Chemotherapy-Free Intervals Influence the Survival of Patients with Recurrent Advanced Epithelial Ovarian Carcinoma: A Retrospective Population-Based Study. Int. J. Environ. Res. Public Health 2021, 18, 6629. https://doi.org/10.3390/ijerph18126629
Huang H-Y, Chiang C-J, Chen Y-Y, You S-L, Hsu H-C, Tang C-H, Cheng W-F. Chemotherapeutic Regimens and Chemotherapy-Free Intervals Influence the Survival of Patients with Recurrent Advanced Epithelial Ovarian Carcinoma: A Retrospective Population-Based Study. International Journal of Environmental Research and Public Health. 2021; 18(12):6629. https://doi.org/10.3390/ijerph18126629
Chicago/Turabian StyleHuang, Hsin-Ying, Chun-Ju Chiang, Yun-Yuan Chen, San-Lin You, Heng-Cheng Hsu, Chao-Hsiun Tang, and Wen-Fang Cheng. 2021. "Chemotherapeutic Regimens and Chemotherapy-Free Intervals Influence the Survival of Patients with Recurrent Advanced Epithelial Ovarian Carcinoma: A Retrospective Population-Based Study" International Journal of Environmental Research and Public Health 18, no. 12: 6629. https://doi.org/10.3390/ijerph18126629